395 related articles for article (PubMed ID: 23232645)
1. Hemodynamic and hormonal changes to dual renin-angiotensin system inhibition in experimental hypertension.
Moniwa N; Varagic J; Ahmad S; VonCannon JL; Simington SW; Wang H; Groban L; Brosnihan KB; Nagata S; Kato J; Kitamura K; Gomez RA; Lopez ML; Ferrario CM
Hypertension; 2013 Feb; 61(2):417-24. PubMed ID: 23232645
[TBL] [Abstract][Full Text] [Related]
2. Restoration of the blood pressure circadian rhythm by direct renin inhibition and blockade of angiotensin II receptors in mRen2.Lewis hypertensive rats.
Moniwa N; Varagic J; Ahmad S; VonCannon JL; Ferrario CM
Ther Adv Cardiovasc Dis; 2012 Feb; 6(1):15-29. PubMed ID: 22222314
[TBL] [Abstract][Full Text] [Related]
3. Long-term safety, tolerability and efficacy of aliskiren in combination with valsartan in patients with hypertension: a 6-month interim analysis.
Chrysant SG; Murray AV; Hoppe UC; Dattani D; Patel S; Hsu H; Zhang J
Curr Med Res Opin; 2008 Apr; 24(4):1039-47. PubMed ID: 18307835
[TBL] [Abstract][Full Text] [Related]
4. Aliskiren enhances the protective effects of valsartan against cardiovascular and renal injury in endothelial nitric oxide synthase-deficient mice.
Yamamoto E; Kataoka K; Dong YF; Nakamura T; Fukuda M; Tokutomi Y; Matsuba S; Nako H; Nakagata N; Kaneko T; Ogawa H; Kim-Mitsuyama S
Hypertension; 2009 Sep; 54(3):633-8. PubMed ID: 19597038
[TBL] [Abstract][Full Text] [Related]
5. The antihypertensive effectiveness and safety of dual RAAS blockade with aliskiren and valsartan.
Chrysant SG
Drugs Today (Barc); 2010 Mar; 46(3):151-62. PubMed ID: 20467589
[TBL] [Abstract][Full Text] [Related]
6. Comparative efficacy of aliskiren/valsartan vs valsartan in nocturnal dipper and nondipper hypertensive patients: a pooled analysis.
Giles TD; Alessi T; Purkayastha D; Zappe D
J Clin Hypertens (Greenwich); 2012 May; 14(5):299-306. PubMed ID: 22533656
[TBL] [Abstract][Full Text] [Related]
7. Effect of add-on aliskiren to type 1 angiotensin receptor blocker therapy on endothelial function and autonomic nervous system in hypertensive patients with ischemic heart disease.
Ozeki A; Amiya E; Watanabe M; Hosoya Y; Takata M; Watanabe A; Kawarasaki S; Nakao T; Watanabe S; Omori K; Yamada N; Tahara Y; Hirata Y; Nagai R
J Clin Hypertens (Greenwich); 2014 Aug; 16(8):591-8. PubMed ID: 25039889
[TBL] [Abstract][Full Text] [Related]
8. Aliskiren and valsartan combination therapy for the management of hypertension.
Epstein BJ
Vasc Health Risk Manag; 2010 Sep; 6():711-22. PubMed ID: 20859542
[TBL] [Abstract][Full Text] [Related]
9. Aliskiren reduces myocardial ischemia-reperfusion injury by a bradykinin B2 receptor- and angiotensin AT2 receptor-mediated mechanism.
Koid SS; Ziogas J; Campbell DJ
Hypertension; 2014 Apr; 63(4):768-73. PubMed ID: 24420538
[TBL] [Abstract][Full Text] [Related]
10. Aliskiren/valsartan combination for the treatment of cardiovascular and renal diseases.
Yarows SA
Expert Rev Cardiovasc Ther; 2010 Jan; 8(1):19-33. PubMed ID: 20030022
[TBL] [Abstract][Full Text] [Related]
11. Aliskiren in combination with valsartan exerts synergistic protective effects against ventricular remodeling after myocardial infarction in mice.
Higashikuni Y; Takaoka M; Iwata H; Tanaka K; Hirata Y; Nagai R; Sata M
Hypertens Res; 2012 Jan; 35(1):62-9. PubMed ID: 21833001
[TBL] [Abstract][Full Text] [Related]
12. Efficacy of aliskiren and valsartan in hypertensive patients with albuminuria: a randomized parallel-group study.
Spanos G; Kalaitzidis R; Karasavvidou D; Pappas K; Siamopoulos KC
J Renin Angiotensin Aldosterone Syst; 2013 Dec; 14(4):315-21. PubMed ID: 23132848
[TBL] [Abstract][Full Text] [Related]
13. Efficacy and safety of combined use of aliskiren and valsartan in patients with hypertension: a randomised, double-blind trial.
Oparil S; Yarows SA; Patel S; Fang H; Zhang J; Satlin A
Lancet; 2007 Jul; 370(9583):221-229. PubMed ID: 17658393
[TBL] [Abstract][Full Text] [Related]
14. Dual inhibition of the renin system by aliskiren and valsartan.
Oparil S; Yarows SA; Patel S; Zhang J; Satlin A
Lancet; 2007 Sep; 370(9593):1126-7. PubMed ID: 17905160
[No Abstract] [Full Text] [Related]
15. Hormonal and hemodynamic effects of aliskiren and valsartan and their combination in sodium-replete normotensive individuals.
Azizi M; Ménard J; Bissery A; Guyene TT; Bura-Rivière A
Clin J Am Soc Nephrol; 2007 Sep; 2(5):947-55. PubMed ID: 17702736
[TBL] [Abstract][Full Text] [Related]
16. Aliskiren, a novel, orally effective renin inhibitor, lowers blood pressure in marmosets and spontaneously hypertensive rats.
Wood JM; Schnell CR; Cumin F; Menard J; Webb RL
J Hypertens; 2005 Feb; 23(2):417-26. PubMed ID: 15662231
[TBL] [Abstract][Full Text] [Related]
17. Beneficial cardiac effects of the renin inhibitor aliskiren in spontaneously hypertensive rats.
van Esch JH; Moltzer E; van Veghel R; Garrelds IM; Leijten F; Bouhuizen AM; Danser AH
J Hypertens; 2010 Oct; 28(10):2145-55. PubMed ID: 20625318
[TBL] [Abstract][Full Text] [Related]
18. Dual inhibition of the renin system by aliskiren and valsartan.
Birkenhäger WH; Staessen JA
Lancet; 2007 Jul; 370(9583):195-196. PubMed ID: 17658374
[No Abstract] [Full Text] [Related]
19. Aliskiren improves left ventricular dysfunction and reduces cardiac dilation in Syrian cardiomyopathic hamsters.
Crespo MJ; Cangiano JL; Altieri PI; Escobales N
J Cardiovasc Pharmacol; 2012 Jun; 59(6):547-52. PubMed ID: 22370958
[TBL] [Abstract][Full Text] [Related]
20. Predominance of AT(1) blockade over mas-mediated angiotensin-(1-7) mechanisms in the regulation of blood pressure and renin-angiotensin system in mRen2.Lewis rats.
Varagic J; Ahmad S; VonCannon JL; Moniwa N; Brosnihan KB; Wysocki J; Batlle D; Ferrario CM
Am J Hypertens; 2013 May; 26(5):583-90. PubMed ID: 23459599
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
